Innoviva Specialty Therapeutics to Deliver Six Presentations from its Infectious Diseases and Critical Care Portfolio at IDWeek 2025

Highlights include an oral presentation of a subset analysis from the Phase 3 clinical trial of zoliflodacin, an investigational single-dose oral treatment for uncomplicated gonorrhea due to Neisseria gonorrhoeae WALTHAM, Mass. --(BUSINESS WIRE)--Oct.